ALEXANDRIA, Va., July 16 -- United States Patent no. 12,360,123, issued on July 15, was assigned to Hoffmann-La Roche Inc. (Little Falls, N.J.).
"E3 ubiquitin ligase (UBE3A) protein targets" was invented by Veronica Costa (Basel, Switzerland), Thomas Peter John Dunkley (Basel, Switzerland), Nikhil Janak Pandya (Basel, Switzerland) and Ravi Jagasia (Basel, Switzerland).
According to the abstract* released by the U.S. Patent & Trademark Office: "The invention relates to UBE3A protein targets and their usage as target engagement biomarkers for compounds that modulate ube3a expression."
The patent was filed on Jan. 15, 2020, under Application No. 17/423,359.
*For further information, including images, charts and tables, please visit: http:/...